title: Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.
abstract: A highly desirable feature for an human immunodeficiency virus type 1 (HIV-1) vaccine is the ability to induce broadly reactive anti-envelope antibodies that can neutralize primary HIV-1 isolates. Two immunizations with an HIV-1 envelope-encoding plasmid together with recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) resulted in high antibody titers in mice. The antibody induction was further enhanced after immunization with genes encoding HIV-1 envelopes originating from subtypes A, B and C. The sera from these animals were able to neutralize A, B and C viral isolates, whereas the sera from animals immunized solely with subtype B DNA neutralized only subtype B virus. The combined DNA vaccine gave serum antibodies with broad recognition of HIV-1 envelope epitopes as determined by peptide mapping. Cell-mediated immunity was not compromised by the increased humoral immunity. This demonstrates the ability of multiple envelope genes to induce the desired antibody response against several subtypes. Moreover, it documents the ability of rGM-CSF to enhance the potency of such a vaccine when given simultaneously. The strategy may be useful for making an HIV vaccine more potent and broadly effective against strains of different clades.
authors.affiliation: Department of Virology, Swedish Institute for Infectious Disease Control and Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Rollman
authors.forename: J
authors.initials: J
authors.lastname: Hinkula
authors.forename: J
authors.initials: J
authors.lastname: Arteaga
authors.forename: B
authors.initials: B
authors.lastname: Zuber
authors.forename: A
authors.initials: A
authors.lastname: Kjerrström
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.forename: Britta
authors.initials: B
authors.lastname: Wahren
authors.forename: Karl
authors.initials: K
authors.lastname: Ljungberg
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000235:genetics*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016233:Immunotherapy, Active / Q000379:methods*; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000627:therapeutic use*
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D019302:HIV Envelope Protein gp160; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D016178:Granulocyte-Macrophage Colony-Stimulating Factor